Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study

• Ngā kaituhi matua: Alice Bitossi (Author), Alessandra Bettiol (Author), Elena Silvestri (Author), Gerardo Di Scala (Author), Daniela Bacherini (Author), Giuseppe Lopalco (Author), Vincenzo Venerito (Author), Florenzo Iannone (Author), Antonio Vitale (Author), Gian Marco Tosi (Author), Domenico Prisco (Author), Stanislao Rizzo (Author), Claudia Fabiani (Author), Luca Cantarini (Author), Gianni Virgili (Author), Lorenzo Vannozzi (Author), Giacomo Emmi (Author)
• Hōputu: Pukapuka
• I whakaputaina: Hindawi Limited, 2019-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Objective. This study was aimed at assessing the long-term ocular control of adalimumab (ADA) in a large real-world population with noninfectious primary or secondary uveitis, focusing on the steroid-sparing effect and on disease-modifying antirheumatic drug (DMARD) cotreatment. Methods. In this ret...